References
- Al-Kindi S, Al-Juhaishi T, Haddad F, Taheri S, Abi Khalil C. Cardiovascular disease research activity in the Middle East: A bibliometric analysis. Therapeutic Advances in Cardiovascular Disease. 2015;9(3):70–76. DOI: 10.1177/1753944715578585
- Yaseen IF, Farhan HA. Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. Frontiers in Cardiovascular Medicine. 2022;9:972455. DOI: 10.3389/fcvm.2022.972455
- Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal. 2022;43(4):280–299. DOI: 10.1093/eurheartj/ehab674
- Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020;22:1945–1960. DOI: 10.1002/ejhf.1920
- Rivero Santana B, Caro Codon J, Juarez Olmos V, et al. HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry. European Heart Journal. 2022;43(Supplement 2):2591–2591. DOI: 10.1093/eurheartj/ehac544.2591
- Volkova M, Russell R
3rd. . Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Current Cardiology Reviews. 2011;7(4):214–220. DOI: 10.2174/157340311799960645 - Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Frontiers of Cardiovascular Medicine. 2020;7:1–14. DOI: 10.3389/fcvm.2020.00026
- Giangiacomi F, Faggiano A, Cardinale D, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series. Frontiers of Cardiovascular Medicine. 2023;10:1–5. DOI: 10.3389/fcvm.2023.1250185
- Eaton H, Timm KN. Mechanisms of trastuzumab induced cardiotoxicity – Is exercise a potential treatment? Cardiooncology. 2023;9:1–10. DOI: 10.1186/s40959-023-00172-3
- Tanaka S, Ikari A, Nitta T, Horiuchi T. Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors. Oxford Medical Case Reports. 2017;2017:129–131. DOI: 10.1093/omcr/omx038
- Zhou S, Cirne F, Chow J, et al. Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab. Oncologist. 2023;28:e712–e722. DOI: 10.1093/oncolo/oyad086
- Patil T, Ali S, Kaur A, et al. Impact of pharmacist-led heart failure clinic on optimization of guideline-directed medical therapy (PHARM-HF). Journal of Cardiovascular Translational Research. 2022;15:1424–1435. DOI: 10.1007/s12265-022-10262-9